CohBar, Inc. to Webcast, Live, at October 1

Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual

NEW YORK, Sept. 28, 2015 /PRNewswire/ -- CohBar, Inc. (OTCQX: CWBR), an innovative biotechnology company focused on developing mitochondria-based therapeutics (MBTs) to treat diseases associated with aging, today announced that CohBar Chairnman Albion Fitzgerald, will present live at on October 1, 2015.

DATE: Thursday, October 1, 2015

TIME: 1:00 pm ET


This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register to save time and receive event updates.

Recent Company Highlights

  • Completed approximately $17million in financings with the January 2015 IPO
  • Listed for trading on the OTCQX Best Marketplace and the TSXV (Toronto Venture Exchange)
  • Opened new advanced laboratory in San Francisco Bay Area (Menlo Park, CA)
  • Signed Research Agreements with the Albert Einstein College of Medicine, the University of Southern California (USC) and the University of Cincinnati  

CohBar lead MBT candidate, MOTS-c, featured in Cell Metabolism, March 2015

Learn more about the event: 

About CohBar
CohBar (OTCQX: CWBR and TSXV: COB.U) is an innovator and leader in the research and development of mitochondria-based therapeutics (MBTs), an emerging new class of drugs targeted for the treatment of diseases associated with aging. MBTs originate from the discovery by our founders of a novel group of peptides within the genome of mitochondria, the energy source within our cells. CohBar's ongoing development of mitochondria-based therapeutics offers potential break-through treatments and improved quality of life for millions of people afflicted with a broad range of diseases including type 2 diabetes, cancer, Alzheimer's and cardiovascular diseases.

For additional company information, please visit

About OTC Markets Group Inc.
OTC Markets Group Inc. operates Open, Transparent and Connected financial markets for 10,000 U.S. and global securities.  Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities.  We organize these securities into markets to inform investors of opportunities and risks: the OTCQX® Best Market; the OTCQB® Venture Market; and the OTC Pink® Open Market.  Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors.  To learn more about how we create better informed and more efficient financial markets, visit

OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.

Subscribe to the OTC Markets RSS Feed

OTC Markets Group, operator of financial markets for 10,000 U.S. and global securities.

About, created by BetterInvesting (NAIC) and PR Newswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

View investor presentations 24/7 at

Forward-Looking Statements
This news release contains forward-looking statements, including: statements concerning: the company's plans, prospects, resources and capabilities including its anticipated research and development activities. Forward-looking statements are based on current expectations, estimates and projections that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated by CohBar. These risks and uncertainties include CohBar's ability to retain key personnel, expand its research operations, and successfully advance its drug discovery and development programs. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at or You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


To view the original version on PR Newswire, visit:

SOURCE CohBar, Inc.